(Q52023443)

20 April 2018

title

Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis. (English)

1 reference

20 April 2018

secondary progressive multiple sclerosis

main subject

0 references

0 references

10

Hartung HP

1 reference

20 April 2018

3

Fazekas F

1 reference

20 April 2018

Petereit HF

1

1 reference

20 April 2018

Pukrop R

2

1 reference

20 April 2018

Bamborschke SU

4

1 reference

20 April 2018

Röpele S

5

1 reference

20 April 2018

Kölmel HW

6

1 reference

20 April 2018

Merkelbach S

7

1 reference

20 April 2018

Japp G

8

1 reference

20 April 2018

Jongen PJ

9

1 reference

20 April 2018

Hommes OR

11

1 reference

20 April 2018

publication date

1 February 2003

1 reference

20 April 2018

Journal of the Neurological Sciences

published in

1 reference

20 April 2018

volume

206

1 reference

20 April 2018

issue

2

1 reference

20 April 2018

page(s)

209-214

1 reference

20 April 2018

Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Intravenous gamma globulin in progressive MS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Pooled human IgG modulates cytokine production in lymphocytes and monocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

The cytokine storm in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Genetic variation at position -1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

An evaluation of interleukin genes fails to identify clear susceptibility loci for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Novel polymorphisms in the IL-10 related AK155 gene (chromosome 12q15)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Interferon-? therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Peripheral nerve injury induces endoneurial expression of IFN-gamma, IL-10 and TNF-alpha mRNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Neuroprotective effects of interleukin-10 following excitotoxic spinal cord injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Anti-inflammatory cytokines: expression and action in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

LPS/IFN-gamma cytotoxicity in oligodendroglial cells: role of nitric oxide and protection by the anti-inflammatory cytokine IL-10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

Exacerbations of multiple sclerosis in patients treated with gamma interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900420-3

10.1016/S0022-510X(02)00420-3

7 January 2021

Identifiers

DOI

1 reference

20 April 2018

1 reference

20 April 2018